Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Psych CASC / OSCEPsychopharmacology — metabolic syndrome and psychotropic monitoring

Psych CASC / OSCE · Psychopharmacology — metabolic syndrome and psychotropic monitoring

Explaining antipsychotic weight gain and a monitoring plan (CASC)

CASC-style station: explain metabolic risk in plain language, validate anger, negotiate monitoring and change options (lifestyle, switch, metformin) without abandoning relapse prevention.

communication2 min readVerification in progress

Target exams

FRANZCPMRCPsychABPNMD-DNB
On this page
Study tools

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
Parents of a 17-year-old with first-episode psychosis are angry that olanzapine has 'made him fat and pre-diabetic' after 10 weeks (plus 8 kg, raised fasting glucose). They want all medication stopped today. The young person is improved and wants to stay well for school exams.

Station instructions (candidate)

You have 7 minutes with the parents (and young person if present). Validate concern about weight and glucose, explain that some antipsychotics — including olanzapine — carry higher metabolic risk especially in young people, outline what monitoring should look like, and negotiate a plan: lifestyle support, possible switch to a lower-metabolic agent, possible metformin, and why abrupt stop of all treatment risks relapse. Avoid jargon without explanation. Do not promise zero risk. Do not dismiss their anger.[1][2][6]

Psychiatry Fellowship Pro

Continue reading

You have read the opening of this CASC / OSCE. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship library.

Sign in to continueSee pricing
References6ShowHide
  1. [1]American Diabetes Association, American Psychiatric Association, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care, 2004.PMID 14747245
  2. [2]Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents JAMA, 2009.PMID 19861668
  3. [3]Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial JAMA, 2008.PMID 18182600
  4. [4]Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder Am J Psychiatry, 2013.PMID 23846733
  5. [5]Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine J Clin Psychiatry, 2008.PMID 18605811
  6. [6]Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry, 1999.PMID 10553730
Psychiatry Fellowship Pro

$29/ monthor $279 / year

The complete Psychiatry Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousExplaining antipsychotic choice and metabolic monitoring (CASC)Psychopharmacology — antipsychoticsNextExplaining bright light therapy for winter depression (CASC)Psychopharmacology — phototherapy and chronotherapy